View Older Stories View More Recent Stories

Sep 1, 2020 09:00AM FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for
Jul 30, 2020 04:01PM Vertex Reports Second-Quarter 2020 Financial Results
Jul 20, 2020 09:01AM Vertex Pharma (VRTX) Announces Positive Phase 3 Study Results for TRIKAFTA in CF
Jul 20, 2020 09:00AM Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating
Jul 16, 2020 01:47PM Vertex Pharmaceuticals Selects TRIA to Design Laboratory and Office for New 268,000 SF VCGT Research Site
Jul 16, 2020 09:00AM Vertex to Announce Second-Quarter 2020 Financial Results on July 30
Jun 25, 2020 09:18AM Vertex and the Vertex Foundation Commit $4 Million to Support Racial Equity and Social Justice
Jun 12, 2020 06:10AM CRISPR Therapeutics (CRSP), Vertex Pharma (VRTX) Highlight New Clinical Data for Investigational Gene-Editing Therapy CTX001 in Severe Hemoglobinopathies
Jun 12, 2020 02:30AM CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congr
Jun 3, 2020 10:02AM Vertex Pharma (VRTX) Names Diana McKenzie to Board
Jun 3, 2020 10:02AM Vertex Pharma (VRTX) Names Diana McKenzie to Board
Jun 3, 2020 10:02AM Vertex Appoints Diana McKenzie to its Board of Directors
May 14, 2020 09:02AM New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
May 11, 2020 09:05AM CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) Announce FDA RMAT Designation Granted to CTX001 for Treatment of Severe Hemoglobinopathies
Apr 29, 2020 04:01PM Vertex Reports First-Quarter 2020 Financial Results
Apr 28, 2020 04:30PM Vertex Announces Virtual 2020 Annual Meeting and Internet Access to Proxy Materials
Apr 27, 2020 08:32AM Vertex Pharma (VRTX), Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies
Apr 27, 2020 08:30AM Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies
Apr 20, 2020 08:30AM Vertex to Announce First-Quarter 2020 Financial Results on April 29
Apr 7, 2020 09:00AM The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response
Mar 27, 2020 08:00AM Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs
Mar 13, 2020 08:00AM The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response
Mar 9, 2020 09:53AM Vertex Pharma (VRTX) Confirms Supply Chain Continuity and 2020 Business Outlook
Mar 9, 2020 09:52AM Vertex Confirms Supply Chain Continuity and 2020 Business Outlook
Mar 2, 2020 03:44PM Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference
Feb 25, 2020 04:01PM Vertex to Present at the Cowen Health Care Conference on March 3
Jan 30, 2020 04:01PM Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results
Jan 21, 2020 04:01PM Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30
Jan 8, 2020 04:01PM Vertex to Present at the J.P. Morgan Healthcare Conference on January 13
Nov 19, 2019 07:02AM CRISPR Therapeutics (CRSP), Vertex (VRTX) Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobino
Nov 19, 2019 07:00AM CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
Nov 18, 2019 07:01AM Vertex (VRTX) and Molecular Templates (MTEM) Establish Pact to Discover, Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants
Nov 7, 2019 04:01PM Vertex to Present at the Credit Suisse Healthcare Conference on November 12
Oct 31, 2019 12:16PM Vertex Pharma (VRTX) Announces Phase 3 Results from Two Studies of TRIKAFTA for CF Concurrently Published in NEJM and The Lancet
Oct 31, 2019 12:15PM Phase 3 Results from Two Studies of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medi
Oct 30, 2019 04:01PM Vertex Reports Third-Quarter 2019 Financial Results
Oct 21, 2019 04:07PM Vertex to Announce Third-Quarter 2019 Financial Results on October 30
Oct 21, 2019 03:56PM Vertex Pharma (VRTX) Confirms FDA Approves TRIKAFTA to Treat Underlying Cause of CF in People Ages 12 and Older Who Have at Least One F508del Mutation
Oct 21, 2019 03:55PM FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation
Oct 21, 2019 03:55PM ADDING MULTIMEDIA FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mut
Oct 1, 2019 08:06AM Vertex Pharma (VRTX) Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer
Oct 1, 2019 08:00AM Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer
Sep 30, 2019 08:02AM Vertex Pharma (VRTX), Ribometrix Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Sep 30, 2019 08:00AM Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Sep 10, 2019 08:30AM Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11
Sep 3, 2019 08:02AM Vertex Pharma (VRTX) to Acquire Semma Therapeutics for $950 Million
Sep 3, 2019 08:00AM Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes
Aug 20, 2019 08:01AM Vertex Pharma (VRTX) Announces FDA Acceptance of VX-445 NDA
Aug 20, 2019 08:00AM FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment
Jul 31, 2019 04:01PM Vertex Reports Second-Quarter 2019 Financial Results
View More Recent Stories View Older Stories